Benign prostatic hyperplasia (BPH) is characterised by the development of lower urinary tract symptoms (LUTS), including voiding and storage problems, and has an increasing incidence in men over the age of 50 years. In the past, transurethral resection of the prostate (TURP) has been considered the standard of care surgical treatment. However, due to increasing adverse effects alternative therapy methods have been on the rise, including water vapour therapy and laser therapy. 

Water vapour therapy

  • Moderate-to-severe LUTS were significantly improved within ≤3 months after thermal therapy and remained consistently durable through 4 years.1
  • Rezūm™ System is considered a minimally invasive alternative for men with moderate-to-severe BPH who do not want to rely on pharmaceutical management of their symptoms. 2
  • The advanced technology can empower urologists to achieve significant clinical improvements and deliver an impactful, durable response for their patients.3
  • Effective symptom relief and improved quality of life remained durable throughout four years using Rezūm. 4
  • Rezūm has a minimal physician learning curve, and early intervention may be a more ideal option for men, rather than pharmaceutical agents or invasive surgery.5
  • Thermal therapy improve symptom scores by approximately 50% throughout 36 months (p <0.0001).6
  • A single water vapour thermal therapy procedure provided effective and durable improvements in symptom scores with lower observed clinical progression rates compared to daily long-term use of pharmaceutical agents.7
  • Convective water vapour thermal therapy provides sustainable improvements for 12 months to lower urinary tract symptoms and urinary flow while preserving erectile and ejaculatory functions.8
  • Identification of treatments for LUTS/BPH that demonstrate cost-effectiveness and provide appreciable symptom relief is paramount as reimbursement for patient care moves from volume-based services to value based services.9, 10

Download further academic publications about water vapour therapy 

Laser therapy

  • Laser therapy has proven to have shorter catheterisation and hospitalisation times compared with TURP1
  • Photoselective vaporisation of the prostate (PVP) using the GreenLight XPS™ -180 W laser system can be considered a safe and durable procedure for patients with BPH needing surgical treatment, with effectiveness maintained for a period of at least 5 years.2
  • The GreenLight XPS laser system has advanced technical specifications compared to previous devices, with a maximum power of 180 W and an improved beam geometry of the MoXy ™ fibre.3
  • PVP decreased the prostate-specific antigen (PSA) level significantly (a reduction of 56%) from 4.5 ng/mL preoperatively to 2.6 ng/mL at 57 months 4
  • The long-term patient satisfaction is high with PVP - 80% (74/84) of the patients were at least mostly satisfied after 57 months5
  • Both PVP and GreenLEP are considered safe and effective for the surgical management of benign prostatic obstruction in patients with large prostate volumes (>80 mL), resulting in satisfactory short-term (6-month) functional outcomes.6

Download further academic publications about laser therapy:

EAU, AUA and NICE guidelines

NEW NICE publishes positive guidance on Rezūm Water Vapour Therapy supporting the case for adopting this minimally invasive BPH treatment in the NHS.

The European Association of Urology (EAU) and the American Urological Association (AUA) regularly publish a reference on effective, evidence-based surgical management of male lower urinary tract symptoms secondary to benign prostatic hyperplasia (LUTS/BPH). These references will provide you with a general recommendation on therapy methods that are considered recognised and safe.

GreenLightTM, AurigaTM XL and RezūmTM are included in the AUA guidelines.

GreenLight and Auriga XL have been fully recognized by the EAU and Rezūm is currently under investigation – an update will follow in due time.
(Last updated on July 1, 2019) 

In addition, the National Institute for Health and Care Excellence (NICE), a non-departmental public body that provides guidance and advice to improve health and social care in England, has provided guidance on vapour therapy, GreenLightand Auriga XL.

NICE also has recently provided positive guidance on Rezūm Water Vapour Therapy supporting the case for adopting this minimally invasive BPH treatment in the NHS.

The BPH decision tree

Through a simple list of yes & no questions, the BPH decision tree has been developed to help during the decision-making process.17 

Stay up to date and subscribe to our newsletter :